TACTI-002: a phase II study of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic NSCLC
Authors
Forster, M.Krebs, Matthew G
Majem, M.
Peguero, J.
Clay, T.
Felip, E.
Iams, W.
Roxburgh, P.
Doger, B.
Bajaj, P.
Kefas, J.
Scott, J. A.
Joaquin, A. B.
Mueller, C.
Triebel, F.
Affiliation
UCL Cancer Institute / University College London Hospitals NHS Foundation, LondonIssue Date
2022
Metadata
Show full item recordCitation
Forster M, Krebs M, Majem M, Peguero J, Clay T, Felip E, et al. TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC. Journal of Thoracic Oncology. 2022 Sep;17(9):S395-S. PubMed PMID: WOS:000858678101128.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2022.07.681Additional Links
https://dx.doi.org/10.1016/j.jtho.2022.07.681Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2022.07.681